165 related articles for article (PubMed ID: 22122360)
1. Differential inhibition of tumour cell-induced platelet aggregation by the nicotinate aspirin prodrug (ST0702) and aspirin.
Medina C; Harmon S; Inkielewicz I; Santos-Martinez MJ; Jones M; Cantwell P; Bazou D; Ledwidge M; Radomski MW; Gilmer JF
Br J Pharmacol; 2012 Jun; 166(3):938-49. PubMed ID: 22122360
[TBL] [Abstract][Full Text] [Related]
2. In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: is this a new immediate-release therapeutic option for niacin?
Ledwidge MT; Ryan F; Kerins DM; O'Connell D; Cefali G; Harmon S; Jones M; Gilmer JF
Atherosclerosis; 2012 Apr; 221(2):478-83. PubMed ID: 22326030
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of aggregation inhibition by aspirin and nitrate-aspirin prodrugs in human platelets.
Harmon S; Inkielewicz-Stepniak I; Jones M; Ledwidge M; Santos-Martinez MJ; Medina C; Radomski MW; Gilmer JF
J Pharm Pharmacol; 2012 Jan; 64(1):77-89. PubMed ID: 22150675
[TBL] [Abstract][Full Text] [Related]
4. Elucidation of flow-mediated tumour cell-induced platelet aggregation using an ultrasound standing wave trap.
Bazou D; Santos-Martinez MJ; Medina C; Radomski MW
Br J Pharmacol; 2011 Apr; 162(7):1577-89. PubMed ID: 21182493
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide.
Jurasz P; Sawicki G; Duszyk M; Sawicka J; Miranda C; Mayers I; Radomski MW
Cancer Res; 2001 Jan; 61(1):376-82. PubMed ID: 11196190
[TBL] [Abstract][Full Text] [Related]
6. Isosorbide-based aspirin prodrugs: integration of nitric oxide releasing groups.
Jones M; Inkielewicz I; Medina C; Santos-Martinez MJ; Radomski A; Radomski MW; Lally MN; Moriarty LM; Gaynor J; Carolan CG; Khan D; O'Byrne P; Harmon S; Holland V; Clancy JM; Gilmer JF
J Med Chem; 2009 Nov; 52(21):6588-98. PubMed ID: 19821574
[TBL] [Abstract][Full Text] [Related]
7. Platelet aggregation-induced by caco-2 cells: regulation by matrix metalloproteinase-2 and adenosine diphosphate.
Medina C; Jurasz P; Santos-Martinez MJ; Jeong SS; Mitsky T; Chen R; Radomski MW
J Pharmacol Exp Ther; 2006 May; 317(2):739-45. PubMed ID: 16424148
[TBL] [Abstract][Full Text] [Related]
8. Single oral dose study of two isosorbide-based aspirin prodrugs in the dog.
Gilmer JF; Murphy MA; Shannon JA; Breen CG; Ryder SA; Clancy JM
J Pharm Pharmacol; 2003 Oct; 55(10):1351-7. PubMed ID: 14607016
[TBL] [Abstract][Full Text] [Related]
9. Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins.
Alonso-Escolano D; Strongin AY; Chung AW; Deryugina EI; Radomski MW
Br J Pharmacol; 2004 Jan; 141(2):241-52. PubMed ID: 14691052
[TBL] [Abstract][Full Text] [Related]
10. Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation.
Jurasz P; Alonso-Escolano D; Radomski MW
Br J Pharmacol; 2004 Dec; 143(7):819-26. PubMed ID: 15492016
[TBL] [Abstract][Full Text] [Related]
11. Abciximab treatment in vitro after aspirin treatment in vivo has additive effects on platelet aggregation, ATP release, and P-selectin expression.
Scazziota A; Altman R; Rouvier J; Gonzalez C; Ahmed Z; Jeske WP; Walenga JM; Fareed J
Thromb Res; 2000 Dec; 100(6):479-88. PubMed ID: 11152927
[TBL] [Abstract][Full Text] [Related]
12. Aspirin does not affect the flow cytometric detection of fibrinogen binding to, or release of alpha-granules or lysosomes from, human platelets.
Chronos NA; Wilson DJ; Janes SL; Hutton RA; Buller NP; Goodall AH
Clin Sci (Lond); 1994 Nov; 87(5):575-80. PubMed ID: 7533066
[TBL] [Abstract][Full Text] [Related]
13. Conditions influencing release of granule contents from human platelets in citrated plasma induced by ADP or the thrombin receptor activating peptide SFLLRN: direct measurement of percent release of beta-thromboglobulin and assessment by flow cytometry of P-selectin expression.
Rand ML; Perry DW; Packham MA; Gemmell CH; Yeo EL; Kinlough-Rathbone RL
Am J Hematol; 1996 Aug; 52(4):288-94. PubMed ID: 8701947
[TBL] [Abstract][Full Text] [Related]
14. Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation.
Sbrana S; Della Pina F; Rizza A; Buffa M; De Filippis R; Gianetti J; Clerico A
Cytometry B Clin Cytom; 2008 Jan; 74(1):30-9. PubMed ID: 17630652
[TBL] [Abstract][Full Text] [Related]
15. Studies on tumor-cell-induced platelet aggregation in human lung cancer cell lines.
Heinmöller E; Weinel RJ; Heidtmann HH; Salge U; Seitz R; Schmitz I; Müller KM; Zirngibl H
J Cancer Res Clin Oncol; 1996; 122(12):735-44. PubMed ID: 8954171
[TBL] [Abstract][Full Text] [Related]
16. Effects of prostacyclin on tumor cell-induced platelet aggregation.
Menter DG; Onoda JM; Taylor JD; Honn KV
Cancer Res; 1984 Feb; 44(2):450-6. PubMed ID: 6362850
[TBL] [Abstract][Full Text] [Related]
17. Triflavin, an Arg-Gly-Asp-containing peptide, inhibits tumor cell-induced platelet aggregation.
Sheu JR; Lin CH; Peng HC; Teng CM; Huang TF
Jpn J Cancer Res; 1993 Oct; 84(10):1062-71. PubMed ID: 8226281
[TBL] [Abstract][Full Text] [Related]
18. The in vitro effects of niacin on platelet biomarkers in human volunteers.
Serebruany V; Malinin A; Aradi D; Kuliczkowski W; Norgard NB; Boden WE
Thromb Haemost; 2010 Aug; 104(2):311-7. PubMed ID: 20539903
[TBL] [Abstract][Full Text] [Related]
19. Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions.
Hosokawa K; Ohnishi T; Sameshima H; Miura N; Ito T; Koide T; Maruyama I
Thromb Haemost; 2013 Jan; 109(1):102-11. PubMed ID: 23179055
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin.
Chakraborty K; Khan GA; Banerjee P; Ray U; Sinha AK
Platelets; 2003; 14(7-8):421-7. PubMed ID: 14713511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
